Introduction
Like other B vitamins, thiamine (vitamin B1, Figure 1a ) is an indispensable molecule for all known organisms. This is mainly because, in mammalian cells, its diphosphorylated form, thiamine diphosphate (ThDP), is the coenzyme for five key metabolic enzymes (Figure 1b) 1 , the most important being mitochondrial pyruvate and oxoglutarate dehydrogenase complexes as well as the cytosolic transketolase. Therefore, it is generally believed that thiamine deficiency leads to decreased oxidative metabolism, which eventually causes cell death. In animals, the brain heavily relies on oxidative metabolism for the synthesis of ATP, making this organ particularly sensitive to thiamine deficiency. In humans, nutritional thiamine deficiency leads to beriberi, a polyneuritic condition, rapidly reversed after thiamine administration. In alcoholics, and also in children, thiamine deficiency can lead to typical selective diencephalic brain lesions 2 generally referred to as Wernicke-Korsakoff syndrome. The reason why some brain regions are more sensitive to thiamine deficiency remains unknown 3 , and it was suggested that this selective vulnerability could be due to a coenzymeindependent role of thiamine or one of its derivatives 4 .
Indeed, in addition to ThDP and free thiamine, several other phosphorylated and adenylated derivatives are observed ( Figure 2 ): thiamine monophosphate (ThMP), thiamine triphosphate (ThTP), adenosine thiamine triphosphate (AThTP) and adenosine thiamine diphosphate (AThDP) 5, 6 . The existence of such forms in many living cells would suggest that they also have some biological role(s). It is indeed worth wondering why the diphosphorylated form of thiamine is the coenzyme, when the monophosphorylated form would do just as well, as is the case for pyridoxal phosphate for instance. It is indeed true that the diphosphate contributes to the binding energy of apoenzymes, but the catalytic properties of thiamine solely rely on the thiazolium ring's ability to lose a proton and form a reactive ylide ( Figure 1c ). Ylide formation is not influenced by the presence of phosphate groups on the hydroxyethyl arm, and there is no obvious advantage to use ThDP (rather than ThMP or ThTP) as coenzyme.
A recent study emphasises beneficial effects of benfotiamine (a thiamine precursor) in a transgenic mouse model of Alzheimer's disease, although only levels of unphosphorylated thiamine were increased in the brain of the animals. Levels of thiaminephosphorylated derivatives, including ThDP, were unaffected 7 . Moreover, it was recently suggested that the Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)
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antinociceptive effects of thiamine in humans and animals could be mediated by the non-phosphorylated form of the vitamin 8 , raising the possibility that free thiamine has pharmacological effects independent of ThDP.
Nearly 20 years ago, we have reviewed data concerning a possible non-coenzyme role of thiamine or its derivatives, particularly in relation to nerve function 9 . Here, we want to critically examine the new data that have been obtained since then.
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964), and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. Animal care was also in accordance with the institution guidelines.
Thiamine derivatives other than ThDP
Thiamine is transported into mammalian cells by specific transporters and immediately phosphorylated to ThDP by cytosolic thiamine pyrophosphokinase ( Figure 2 ). ThDP can then be phosphorylated to ThTP or transformed to adenylated derivatives. However, the most obvious fate for cytosolic-free ThDP is hydrolysis 
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Critical review nism (ThDP + Pi � ThTP) [14] [15] [16] in intact E. coli cells and isolated brain mitochondria. Interestingly both mechanisms are conserved from bacteria to mammals. However, while the synthesis by adenylate kinase seems to be constitutive and is probably merely a side reaction, the synthesis by FoF1-ATP synthase is strongly dependent on metabolic conditions. While on one hand there is presently no evidence for a specific enzyme involved in ThTP synthesis, on the other hand, mammalian cells contain a highly specific thiamine triphosphatase (ThTPase) [17] [18] [19] . This 25 kDa cytoplasmic protein is a highly efficient ThTPase ubiquitously expressed in adult mammalian tissues. However, it seems to be most abundant in highly differentiated cells while it is hardly detectable in cultured cells, suggesting that to ThMP, which is recycled to thiamine. No specific enzymes have been identified for the latter reactions, and there is no known role for ThMP. Intracellular ThMP levels are generally much lower than ThDP levels. However, ThMP seems to be excreted, probably by a process involving the reduced folate carrier (RFC1 or SLC19A1) 10 , a transporter closely related to thiamine transporters, and it is present in extracellular fluids such as blood plasma, cerebrospinal fluid (CSF) and breast milk.
The case of ThTP
ThTP is a particularly intriguing molecule. It is found in nearly all organisms and is the only known triphosphorylated compound that is not a nucleotide. With two phosphoanhydride bonds, it is an energyrich compound, and as such it has been shown to be able to phosphorylate proteins 11 , although it is not clear whether such phosphorylation is of physiological significance. While ThTP seems to be constitutively synthesised in animal cells, in Escherichia coli, it accumulates only in the absence of amino acids and therefore could be a signalling molecule involved in the adaptation to amino acid starvation 12 . While it was long thought that ThTP is synthesised by an ATP:ThDP phosphotransferase, the existence of such a mechanism has never been unambiguously demonstrated. It appears now that two ATP-synthesising mechanisms may be diverted towards the synthesis of ThTP: one using adenylate kinase isoform 1 (AK1) (ThDP + ADP � ThTP + AMP) 13 and another via FoF1-ATP synthase by a chemiosmotic mecha- (2) yields ThMP, which in turn can be hydrolysed to thiamine by thiamine monophosphatases (3) . ThDP can be phosphorylated to ThTP by two mechanisms: mitochondrial FoF1-ATP synthase (4) and cytosolic adenylate kinase (5) . ThTP can be hydrolysed to ThDP by a very specific cytosolic 25 kDa thiamine triphosphatase (6) . ThDP can also be converted to AThTP by a ThDP adenylyl transferase (7) . AThTP can be hydrolysed to ThDP and AMP by a putative AThTP hydrolase (8) . AThDP has been shown to exist in prokaryotes and eukaryotes, but its mechanism of synthesis has not yet been demonstrated in vitro.
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It was suggested that ThTPase is a repair enzyme whose role is to remove potentially toxic ThTP produced as a by-product of the above-mentioned reactions 22 . However, in those organisms where 25 kDa ThTPase is absent (chicken) or catalytically inefficient (fish, pig), cytosolic ThTP indeed accumulates, and in skeletal muscles and electric organs, its levels can even exceed those of ThDP but without apparent toxic effect 21 . It is possible that ThTP has mainly a mitochondrial role, that is, intramitochondrial ThTP synthesised by FoF1-ATP synthase is the physiologically relevant pool, while cytosolic ThTP synthesised by adenylate kinase would be only a by-product of this enzyme activity. In this respect, cytosolic ThTP concentrations might just reflect the abundance of AK1 in the absence of 25 kDa ThTPase.
Adenylated thiamine derivatives
AThTP (or thiaminylated ATP, Figure 2 ) was first discovered in E. coli, where it accumulates in response to carbon starvation or uncoupling 5, 23 . While other B vitamins have long been known to form coenzymes by combination with adenylate (riboflavin in FAD, nicotinic acid in NAD + , pantothenic acid in CoA for instance), this was the first time that such a condensation product was demonstrated for thiamine. AThTP exists in small amounts not only in animals and plants (mainly in roots) but also in many cultured mammalian cells 21 . AThTP was shown to be an inhibitor of poly(ADP-ribose) polymerase-1 in vitro 24 . Moreover, small amounts of AThDP were also discovered in various organisms 6 .
Thiamine-binding proteins
We refer here to proteins that specifically bind thiamine or one of its phosphorylated derivatives, but the bound thiamine compound is not supposed to act as a coenzyme. Likewise, we shall not consider enzymes using thiamine derivatives as substrates (i.e. enzymes involved in the metabolism of phosphoryl derivatives, see Figure 2 ) nor thiamine transporters.
Several proteins that specifically bind the unphosphorylated form of the vitamin have been described. Some are thiamine-storage proteins, and they were characterised mainly in plant tissues. In mammals, a few thiamine-binding proteins have been described, but their possible roles remain unclear. Such a protein has been purified from rat erythrocytes 25 . It is a soluble 32 kDa protein binding unphosphorylated thiamine. It is not clear whether it also binds phosphate esters or whether it is specific. The group of Yulia Parkhomenko in Kiev extensively studied thiamine-binding proteins from brain. By affinity chromatography (thiamine covalently bound to a Sepharose 4B matrix), they isolated a thiamine-binding protein from a synaptosomal acetone powder 26 . This 103-107 kDa protein also binds ThMP and ThTP and to a lesser extent ThDP. The same group later showed that the thiaminebinding activity is mainly associated with synaptic vesicles and synaptosomal membranes 26 . It was also claimed that this thiamine-binding proteins had ThTPase activity 27 , but this has not yet been proven using a purified homogenous protein preparation. If this synaptosomal thiaminebinding protein is indeed a membraneassociated membrane protein, it could act as a presynaptic 'thiamine receptor'. There is some evidence that thiamine can act as a neuromodulator at some synapses, regulating neurotransmitter release (see next section). It is also worth pointing out that the antinociceptive effect of thiamine seems to require prostatic acid phosphatase, which could act as or be part of a thiamine receptor 8 .
Synaptosomes prepared from Torpedo electric organ are enriched in thiamine and its phosphate esters, while synaptic vesicles are not, suggesting that they are localised in the axoplasm 28 . Another study suggested that thiamine is an integral component of synaptosomal membranes 29 . A role of thiamine in mammalian neuromuscular transmission has also been suggested in other studies 30 . Taken together, all those data suggest that thiamine may have a specific, coenzyme-independent role in synapses. The existence of ThDP-binding proteins other than apoenzymes using ThDP as coenzyme has long been debated. Cooper and associates claimed that protein-bound ThDP, isolated from a soluble liver fraction, was the substrate for ThTP synthesis 31 , but it was later shown that the only ThDPbinding protein in liver cytosol was transketolase 32 . In rat brain, Yoshioka et al. described the immunohistochemical localisation of a 68 kDa ThDP-binding protein 33 . In this case too, the protein probably corresponds to transketolase as the molecular mass is about the same.
Thiamine in neurotransmitter release
A specific neuroactive role of thiamine in relation to nerve excitability has been postulated as early as the 1940s, and these data have been previously reviewed 9 . While there is presently no convincing evidence that thiamine has physiologically relevant effects on axonal conductance, it has been reported consistently that thiamine (and/or some of its phosphate esters) facilitates neurotransmission in various preparations, probably by potentiation of the release of the neurotransmitters acetylcholine 28, 34, 35 , dopamine 36 and noradrenaline 35 . Here, we are exclusively interested in direct (rapid) effects on neurotransmission, as in chronic experiments (for instance, after administration of thiamine for several weeks in animals), it is very difficult to discriminate between putative coenzyme-independent and coenzyme-dependent effects: for instance, increased pyruvate
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In addition to thiamine, several thiamine antimetabolites, the most widely used being pyrithiamine and oxythiamine (Figure 3) , have been tested. These structural analogues of thiamine are called antimetabolites, as when administered to animals they produce signs of thiamine deficiency, pyrithiamine acting primarily centrally and oxythiamine acting peripherally as it presumably does not cross the blood-brain barrier. Both compounds competitively inhibit thiamine transport 37 and ThDP synthesis by thiamine pyrophosphokinase 38, 39 (although pyrithiamine is more effective).
The fact that they are antimetabolites does not preclude the possibility that they may also act as thiamine agonists when thiamine acts as a non-coenzyme modulator. Indeed, oxythiamine stimulates potassiumevoked acetylcholine release in the presence of Ca 2+ in isolated brain slices 40 .
These results suggest a coenzymeindependent effect of thiamine on neurotransmitter release, affecting at least three different neurotransmitters (acetylcholine 28, 34, 35 , dopamine 36 and noradrenaline 35 ) in different preparations ranging from fish electric organ to mammalian brain. This suggests a rather conserved mechanism. Conversely, thiamine deficiency leads to synaptic vesicle dysfunction with decreased release of dopamine 41 , glutamate 42 or acetylcholine 43 . Moreover, episodes of pyrithiamineinduced thiamine deficiency in the rat lead to a significant reduction in phosphosynapsin I 44 . Although, the animals were treated for 3 weeks with thiamine after appearance of thiamine deficiency symptoms (loss of righting reflex and seizures), the reduction of phosphosynapsin was not reversed. Thus, reduction of phosphosynapsin appears to be an epigenetic phenomenon that cannot be explained by decrease in ThDPdependent enzyme activities; indeed, ThDP levels should have been restored by thiamine treatment. It can indeed not be explained by a decrease in ThDP-dependent enzyme activities, as brain thiamine and ThDP levels have presumably been restored. It is thought that phosphorylation of synapsin I leads to a detachment of synapsin from the synaptic vesicles allowing their fusion with the presynaptic membrane and neurotransmitter release. An interesting hypothesis would be that thiamine, directly or indirectly, acts on synapsin I, thereby promoting neurotransmitter release.
This effect could be antagonised by pyrithiamine.
Potential non-coenzyme roles of thiamine and its derivatives are summarised in Figure 4 .
Thiamine in stress, diabetes and neurodegenerative diseases
In many instances, beneficial and probiotic effects of thiamine (and/or pharmaceutical preparations of thiamine precursors with higher bioavailability) have been demonstrated. In these cases, we are most likely dealing with pharmacological effects as therapeutic (superphysiological) doses were used. Indeed, under laboratory conditions, either animals or cultured cells are generally in a thiamine-rich According to some reports, thiamine increases disease resistance in plants 45, 46 . Moreover, intracellular thiamine and thiamine phosphate pools are regulated by various stress conditions in Zea mays and Arabidopsis thaliana seedlings; it was suggested that thiamine is a signalling molecule important for the adaptation to various stress conditions 47, 48 . Interestingly, such a signalling role is assigned to unphosphorylated thiamine in plants, while it should be assigned to ThTP and AThTP in E. coli 5,6,12 (see above). Note that in Arabidopsis leaves, ThTP accumulates during withering 49 . Protective effects of thiamine have also been described in mammalian cells: thiamine protects retinal neurons against glutamate toxicity 50 and promotes the survival of hippocampal neurons in high cell density culture 51 .
Thiamine requires specific transporters to enter cells 52 . As the rate of transport by these transporters is relatively slow, membrane transport is a rate-limiting step in thiamine homeostasis. For that reason, synthetic thiamine precursors were developed. These molecules are either relatively hydrophobic (sulbutiamine, fursultiamine) or are converted to a hydrophobic precursor (benfotiamine) allowing them to cross membranes relatively freely ( Figure  3) . The general effect of these derivatives is to rapidly increase circulating thiamine to levels higher than those obtained by an equivalent dose of thiamine. It must be emphasised than none of these precursors have ever been demonstrated to reach the brain parenchyma. They are all converted to thiamine either during the passage from intestine to blood or in the liver. As the blood-brain barrier strongly limits thiamine uptake by the brain (thiamine entry could be limited by a self-exchange), no important increase in brain thiamine levels are observed even with these derivatives 7, [53] [54] [55] . It would therefore be interesting to synthesise derivatives that have a half-life sufficiently long to reach significant blood levels to cross the blood-brain barrier.
Nonetheless, thiamine and/or thiamine precursors have been shown to have beneficial effects in diabetes and an animal model of Alzheimer's disease 7, 56, 57 . One study has shown improved cognitive functions and a striking decrease in charge of β-amyloid plaques in a mouse model of Alzheimer's disease 58 . This study, however, needs confirmation.
A relationship between thiamine and Parkinson's disease has recently been suggested 59, 60 . It had previously been shown that free thiamine levels are decreased in the CSF of patients with Parkinson's disease compared with control patients 61 . Moreover, a very recent preliminary clinical study reported the beneficial effects of thiamine treatment (100-200 mg daily doses of parenteral thiamine) on a limited number of patients 62 . This again needs confirmation.
Conclusion
Thiamine, by the number of its derivatives, is certainly one of the most diverse B vitamins. By virtue of the role of ThDP as coenzyme of several key enzymes, it is involved in nearly all aspects of cell metabolism: energy production, ribose and nucleic acid synthesis, lipid biosynthesis and neurotransmitter synthesis to name only the most important. Therefore, thiamine is particularly important for the nervous system, which is highly sensitive to thiamine deficiency. However, the existence of potential non-coenzyme roles remains a puzzling issue. First, the existence of triphosphorylated derivatives, unable to replace the coenzyme ThDP, is highly suggestive of such roles. ThTP and AThTP may be involved in some signalling processes under specific conditions of cellular stress. Second, thiamine itself, possibly through specific thiaminebinding proteins, may regulate processes such as neurotransmitter release and in plants protect against disease and stress. Although there is still no direct evidence for a physiologically important non-coenzyme role of thiamine, in view of the potential therapeutic interest of thiamine in Alzheimer's and Parkinson's diseases, this may become a key issue in the future.
